Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply

Detalles Bibliográficos
Autores principales: Nakaoka, Yoshikazu, Yamashita, Katsuhisa, Yamakido, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Matters Arising
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449802/
https://www.ncbi.nlm.nih.gov/pubmed/32594147
http://dx.doi.org/10.1093/rheumatology/keaa255
_version_ 1783574693183225856
author Nakaoka, Yoshikazu
Yamashita, Katsuhisa
Yamakido, Shinji
author_facet Nakaoka, Yoshikazu
Yamashita, Katsuhisa
Yamakido, Shinji
author_sort Nakaoka, Yoshikazu
collection PubMed
description
format Online
Article
Text
id pubmed-7449802
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-74498022020-08-31 Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply Nakaoka, Yoshikazu Yamashita, Katsuhisa Yamakido, Shinji Rheumatology (Oxford) Matters Arising Oxford University Press 2020-09 2020-06-28 /pmc/articles/PMC7449802/ /pubmed/32594147 http://dx.doi.org/10.1093/rheumatology/keaa255 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Matters Arising
Nakaoka, Yoshikazu
Yamashita, Katsuhisa
Yamakido, Shinji
Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
title Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
title_full Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
title_fullStr Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
title_full_unstemmed Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
title_short Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply
title_sort comment on: long-term efficacy and safety of tocilizumab in refractory takayasu arteritis: final results of the randomized controlled phase 3 takt study: reply
topic Matters Arising
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449802/
https://www.ncbi.nlm.nih.gov/pubmed/32594147
http://dx.doi.org/10.1093/rheumatology/keaa255
work_keys_str_mv AT nakaokayoshikazu commentonlongtermefficacyandsafetyoftocilizumabinrefractorytakayasuarteritisfinalresultsoftherandomizedcontrolledphase3taktstudyreply
AT yamashitakatsuhisa commentonlongtermefficacyandsafetyoftocilizumabinrefractorytakayasuarteritisfinalresultsoftherandomizedcontrolledphase3taktstudyreply
AT yamakidoshinji commentonlongtermefficacyandsafetyoftocilizumabinrefractorytakayasuarteritisfinalresultsoftherandomizedcontrolledphase3taktstudyreply

Ejemplares similares